Posaconazole
From Wikipedia, the free encyclopedia
 |
|
|
Posaconazole
|
|
| Systematic (IUPAC) name | |
| 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)tetrahydro- 5-(1H-1,2,4-triazol-1-ylmethyl)-3-furanyl]methoxy] phenyl]-1-piperazinyl]phenyl]-2-[(1S,2S)-1-ethyl- 2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one |
|
| Identifiers | |
| CAS number | ? |
| ATC code | J02AC04 |
| PubChem | 147912 |
| Chemical data | |
| Formula | C37H42N8F2O4 |
| Mol. weight | 700.778 g/mol |
| Pharmacokinetic data | |
| Bioavailability | High |
| Protein binding | 98 to 99% |
| Metabolism | Hepatic glucuronidation |
| Half life | 16 to 31 hours |
| Excretion | Fecal (77%) and renal (14%) |
| Therapeutic considerations | |
| Licence data | |
| Pregnancy cat. |
C(US) |
| Legal status |
℞-only(US) |
| Routes | Oral |
Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. There is also limited clinical evidence for its utility in treatment of invasive disease caused by Fusarium species (fusariosis).[1]
[edit] References
- ^ Raad I, Hachem R, Herbrecht R, et al. (2006). "Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions". Clin Infect Dis 42 (10): 1398–1403.
| Antifungals (D01 and J02) edit | ||
|---|---|---|
| Antibiotics: | Griseofulvin, Hitachimycin, Natamycin, Nystatin | |
| Topical Azoles: | Clotrimazole, Econazole, Fluconazole, Ketoconazole, Miconazole, Oxiconazole, Sertaconazole, Sulconazole, Tioconazole | |
| Other topicals: | Ciclopirox, Ethylparaben, Flucytosine, Salicylic acid, Selenium sulfide, Terbinafine, Tolnaftate | |
| For systemic use: | Amphotericin B, Anidulafungin, Caspofungin, Griseofulvin, Itraconazole, Terbinafine, Voriconazole | |
| Other: | Posaconazole, Thiabendazole, Tea tree oil | |
